PMOS and Your Heart: What the Cardiovascular Risk Actually Is

Somewhere in the years of being told to lose a bit of weight and come back, a different sentence sometimes lands: that PCOS — now PMOS, after the Lancet consensus paper in May 2026 — is "a heart risk." It's true, and it's worth taking seriously. It's also easy to hear it as a verdict when it's really a reason to get a few tests. So here's the honest version: how much higher the risk actually is, where the evidence is solid and where it's still messy, and what a thirty-something with PMOS can do about it now rather than at sixty.

PMOS was renamed precisely because the heart-and-metabolism side of it turned out to be the main event, not a footnote to the ovaries. The same insulin resistance that drives irregular cycles is the thread running to blood pressure, cholesterol, and blood sugar — we mapped that whole-body picture in the PMOS body map. This piece zooms in on one room: the heart.

What the big numbers actually say

The clearest answer we have comes from the systematic review and meta-analysis that informed the 2023 International Evidence-Based PCOS Guideline, published in the Journal of the American Heart Association in 2024. It pooled 20 studies and more than a million women — about 369,000 with PMOS and 693,000 without.

The headline: women with PMOS had higher odds of cardiovascular disease overall (odds ratio 1.68), of stroke (1.71), and most sharply of heart attack (myocardial infarction odds ratio 2.50). In the studies that followed women forward over time, the elevated risk held up for composite cardiovascular disease and heart attack, though the signal for stroke was weaker.

Two things are worth holding onto. The relative risk of a heart attack being roughly two-and-a-half times higher sounds alarming — but it's a multiple of an absolute risk that is low for most women in their thirties and forties to begin with. And the same analysis found no statistically significant increase in death from cardiovascular causes. The risk is real and worth acting on early; it is not a sentence.

The honest hedge: where the evidence thins

Most of these numbers are associations from cohort and cross-sectional studies, not proof that PMOS causes a heart attack in any one person. The bigger gap is age. Nearly all the studies enrolled younger women, and most didn't record menopausal status — so the meta-analysis authors declined to draw firm conclusions about the post-menopausal years.

That matters, because the open question is whether the risk fades as periods end or keeps climbing. A 13-year follow-up of an unselected PMOS cohort (Journal of Endocrinology and Investigation, 2024) found the cardiometabolic risk profile persisting over time rather than resolving. And our PMOS-versus-perimenopause piece makes the same point from the other side: the metabolic part of PMOS doesn't retire when the reproductive part does. The reproductive-age risk is well established. The menopausal-age picture is genuinely still being worked out — which is a reason to keep monitoring, not to assume you're in the clear.

What raises the risk — and what lowers it

The lever underneath the heart numbers is the same one underneath everything else: insulin resistance, plus the blood pressure, cholesterol, and blood-sugar drift that travel with it. Type 2 diabetes risk runs roughly two to four times the general rate, and the glucose drift often starts years before anyone names it. In Asian women, this arrives at a lower weight — which is why we flag metabolic risk from a BMI of 23, not the Western 25, and why a normal BMI doesn't clear you.

The hopeful half is that the things that lower insulin resistance tend to move the heart numbers too. The supplements that match your subtype and, for some women, the GLP-1 evidence act on the shared root. There are even surprising levers: a 2026 analysis found that among women with PMOS who'd had a complicated pregnancy, exclusive breastfeeding was independently linked to far lower cardiometabolic risk at 18 months (adjusted odds ratio 0.14) — one of several signs that this risk is modifiable, not fixed.

What to ask for

The single most useful shift is to stop thinking "period problem" and start thinking "metabolic condition that happens to show up in the cycle." That reframe is what gets the right tests ordered. At a routine visit, it's reasonable to ask for a blood pressure reading on the record, a fasting lipid panel, and a fasting glucose or HbA1c — and, if your history warrants it, fasting insulin to read insulin resistance directly rather than waiting for glucose to drift. None of this is exotic; it's the standard cardiometabolic check, ordered a decade earlier than it otherwise would be.

That earlier conversation is, quietly, the whole point. A 2026 qualitative study found most women with PMOS are still managing it alone, without coordinated support — which is exactly the gap that lets a screenable risk go unscreened for years.

You don't need to overhaul your life over this. You need the next appointment to ask bigger questions. If you want to see which parts of this apply to you, our free 5-minute assessment walks through your symptoms and subtype — and shows you a result without asking for anything in return.

Citations

• Teede HJ, et al. The Lancet, 12 May 2026 — the PMOS rename consensus.
• 2023 International Evidence-Based PCOS Guideline Update — systematic review and meta-analysis on elevated clinical cardiovascular disease in PCOS, Journal of the American Heart Association, 2024 (20 studies, >1M women; composite CVD OR 1.68, MI OR 2.50, stroke OR 1.71; cardiovascular death not significant).
• Aksun S, et al. Alterations of cardiometabolic risk profile in PCOS: 13-year follow-up in an unselected population. Journal of Endocrinology and Investigation, 2024.
• Palomba S, et al. Effect of breastfeeding on cardiometabolic risk in patients with PCOS. Journal of Endocrinology and Investigation, 2026 (composite cardiometabolic outcome 55.4% vs 11.4%; exclusive breastfeeding adjusted OR 0.14).
• 2023 International Evidence-Based Guideline for the assessment and management of PCOS — CVD risk-assessment recommendation.